Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Core Viewpoint - Clearmind Medicine Inc. has filed its Annual Report on Form 20-F for the fiscal year ended October 31, 2025, with the U.S. Securities and Exchange Commission, highlighting its focus on developing novel neuroplastogen-derived therapeutics to address significant health issues [1]. Company Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company dedicated to discovering and developing psychedelic-derived therapeutics aimed at addressing widespread health problems, including alcohol use disorder [3]. - The company's primary goal is to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [3]. Intellectual Property - Clearmind's intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [4]. Stock Information - Shares of Clearmind are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under the symbol "CWY0" [4]. Investor Relations - Shareholders can access the Annual Report on the SEC's website or Clearmind's Investor Relations website, and can request copies of the report free of charge [2].